Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden

Overview of attention for article published in Frontiers in oncology, March 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 5 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 12,320 followers.

Frontiers | Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden https://t.co/8RW78Ui5Uq #cytofpub

22 Mar 2023

Reply Repost Favourite

RT @FrontOncology: New research: Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancrea…

07 Mar 2023

Reply Repost Favourite

RT @FrontOncology: New research: Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancrea…

07 Mar 2023

Reply Repost Favourite

New research: Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden: Single-agent immune checkpoint blockade has shown no clinical benefits… https://t.

07 Mar 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.